UK's NHS drugs bill is L10.7B, diabetes up 88%
The UK National Health Service drug bill is now 10.70 billion ($3.31 billion), according to a review of the public health care system's future by Lord Darzi for the government. The chief executive of the NHS Alliance, Mike Sobanja, noted in the February edition of the Health Direction Monthly Newsletter, that of particular concern is the finding that diabetes is now the largest cost element to the NHS drugs bill, at over L500.0 million.
Diabetes drug spending has "increased by an astonishing 88%" in the past five years, Mr Sobanja said. "More and rigorous attention to prescribing going forward as commissioners get to grips with their new roles," can be expected, he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze